Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Acarbose | Semaglutide | |
|---|---|---|
| Category | Pharmaceuticals | Pharmaceuticals |
| Standard Dose | Research indicates 25-100 mg taken with the first bite of each carbohydrate-containing meal, up to 3 times daily. | Research indicates 0.25 mg weekly SC for 4 weeks, escalating to 0.5 mg, then 1.0 mg, then 1.7 mg, then 2.4 mg weekly (FDA weight management protocol). Oral: 3 mg daily for 30 days, then 7 mg, then 14 mg daily. |
| Timing | Must be taken with the first bite of a carbohydrate-containing meal — timing is critical for mechanism of action. Ineffective if taken without carbohydrates or after the meal. | SC injection any time of day, with or without food, on the same day each week. Oral: take on empty stomach with no more than 4 oz water, 30+ minutes before first food/drink/medications. |
| Cycle Duration | Ongoing for longevity applications. Long-term use is well-established in diabetes management. | Long-term/continuous use. Weight regain occurs upon discontinuation (67% regain within 1 year in trials). |
| Evidence Level | animal_plus_anecdotal | Strong (FDA-approved) |
Acarbose is a complex oligosaccharide that competitively inhibits alpha-glucosidase enzymes (maltase, isomaltase, sucrase, glucoamylase) in the brush border of the small intestinal enterocytes, delaying the digestion and absorption of dietary carbohydrates. This blunts postprandial glucose and insulin spikes, reducing glycemic variability. In the longevity context, chronic postprandial glucose/insulin reduction mimics aspects of caloric restriction signaling, potentially reducing mTOR activation, AGE formation, and oxidative stress. Undigested carbohydrates reaching the colon serve as prebiotics, increasing short-chain fatty acid (SCFA) production by gut bacteria.
Research indicates 25-100 mg taken with the first bite of each carbohydrate-containing meal, up to 3 times daily.
Must be taken with the first bite of a carbohydrate-containing meal — timing is critical for mechanism of action. Ineffective if taken without carbohydrates or after the meal.
Ongoing for longevity applications. Long-term use is well-established in diabetes management.
Semaglutide is a GLP-1 receptor agonist with 94% structural homology to native GLP-1, modified with amino acid substitutions and a C-18 fatty acid chain that enables albumin binding, extending half-life to approximately 7 days. Centrally, it activates anorexigenic POMC/CART neurons and inhibits orexigenic NPY/AgRP neurons in the arcuate nucleus of the hypothalamus, reducing hunger and increasing satiety. Peripherally, it slows gastric emptying, enhances glucose-dependent insulin secretion from pancreatic beta-cells, and reduces glucagon secretion, providing comprehensive metabolic regulation.
Research indicates 0.25 mg weekly SC for 4 weeks, escalating to 0.5 mg, then 1.0 mg, then 1.7 mg, then 2.4 mg weekly (FDA weight management protocol). Oral: 3 mg daily for 30 days, then 7 mg, then 14 mg daily.
SC injection any time of day, with or without food, on the same day each week. Oral: take on empty stomach with no more than 4 oz water, 30+ minutes before first food/drink/medications.
Long-term/continuous use. Weight regain occurs upon discontinuation (67% regain within 1 year in trials).
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →